Measurement of anti-beta amyloid antibodies in human blood

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 167-174

  Szabo, Paul ^a   Mujalli, Diana M ^a   Rotondi, Matthew L ^a   Sharma, Rajal ^a   Weber, Alfred ^b   Schwarz, Hans Peter ^b   Weksler, Marc E ^a   Relkin, Norman ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Baxter Biosciences   (Austria)

Author keywords

Avidity; Beta Amyloid; Endogenous anti A antibodies; Polyvalent antibodies

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; MONOMER; POLYSTYRENE; SODIUM CHLORIDE; AMYLOID BETA PROTEIN; PROTEIN BINDING;

ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CHROMATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; PROCEDURES; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; PROTEIN BINDING; AMYLOID BETA-PEPTIDES;

EID: 77956651669     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.06.010     Document Type: Article

References (30)

1. Akerström B., Björck L. A physicochemical study of protein G, a molecule with unique immunoglobulin G-binding properties. J. Biol. Chem. 1986, 261:10240-10247.
2. 1-42 oligomer - a homogeneous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
3. Baumketner A., Berstein S.L., Wyttenbach T., Bitan G., Teplow D.B., Bowers M.T., Shea J.-E. Amyloid β-protein monomer structure: a computational and experimental study. Prot. Sci. 2006, 15:420-428.
4. Bouvet J.P., Stahl D., Rose S., Quan C.P., Kazatchkine M.D., Kaveri S.V. Induction of natural autoantibody activity following treatment of human immunoglobulins with dissociating agents. J. Autoimmun. 2001, 16:163-172.
5. 1-42 peptide. Biol. Psychiatry 2005, 57:813-816.
6. Britshgi M., Olin C.E., Johns H.T., Takeda-Uchimura Y., LeMieux M.C., Rufibach K., Rajadas J., Zhang H., Tomooka B., Robinson W.H., Clark C.M., Fagan A.M., Galasko D.R., Holtzman D.M., Jutel M., Kaye J.A., Lemere C.A., Leszek J., Peskind E.R., Quinn J.F., Yesavage J.A., Ghiso J.A., Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl Acad. Sci. USA 2009, 106:12145-12150.
7. Dimitrov J.D., Lacroix-Desmazes S., Kaveri S.V., Vassilev T.L. Transition towards antigen-binding promiscuity of a monospecific antibody. Molec. Immunol. 2007, 44:1854-1863.
8. Djoumerska I., Tchorbanov A., Pashovyz A., Vassilev T. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand. J. Immunol. 2005, 61:357-363.
9. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., Hemmeter U., Paulsen S., Teipel S.J., Brettschneider S., Spottke A., Nolker C., Moller H.J., Wei X., Farlow M., Sommer N., Oertel W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:1472-1474.
10. Du Y., Xing Wei X., Dodel R., Sommer N., Hampel H., Gao F., Ma Z., Liming Zhao, Oertel W., Farlow M. Human anti-ß-amyloid antibodies block ß-amyloid fibril formation and prevent ß-amyloid-induced neurotoxicity. Brain 2003, 126(9):1935-1939.
11. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X., Mayeux R. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 2001, 49:808-810.
12. Istrin Gili, Bosis Eran, Solomon Beka Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. J. Neurosci. Res. 2006, 84(2):434-443.
13. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
14. Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L., Rasool S., Gurlo T., Butler P., Glabe C.G. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegeneration 2007, 2:18-29.
15. Klaver Andrea C., Patrias Lynnae M., Coffey Mary P., Finke John M., Loeffler David A. Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J. Neurosci. Meth. 2010, 187:263-269.
16. Li Q., Gordon M., Cao C., Ugen K.E., Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci. 2007, 8:22.
17. Moir R.D., Tseitlin K.A., Soscia S., Hyman B.T., Irizarry M.C., Tanzi R.E. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J. Biol. Chem. 2005, 280:17458-17463.
18. Mruthinti S., Buccafusco J.J., Hill W.D., Waller J.L., Jackson T.W., Zamrini E.Y., Schade R.F. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol. Aging 2004, 25:1023-1032.
19. Nath A., Hall E., Tuzova M., Dobbs M., Jons M., Anderson C., Woodward J., Guo Z., Fu W., Kryscio R., Wekstein D., Smith C., Markesbery W.R., Mattson M.P. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003, 3:29-39.
20. + T cells in healthy individuals. Eur. J. Immunol. 2001, 31:2660-2668.
21. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl Acad. Sci. USA 2002, 99:1485-1490.
22. O'Nuallain B., Hrncic R., Wall J.S., Weiss D.T., Solomon A. Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J. Immunol. 2006, 176:7071-7078.
23. O'Nuallain B., Acero L., Williams A.D., McWilliams-Koeppen H.P., Weber A., Schwarz H.P., Wall J.S., Weiss D.T., Solomon A. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008, 47:12254-12256.
24. Pullen G.R., Fitzgerald M.G., Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods. 1986, 86:83-87.
25. Relkin N.R., Mujalli D., Shennoy S.A., Adamiak B., Weksler M.E., Kayed R., Glabe C., Szabo P. IVIG contains antibodies against oligomers and fibrils of beta amyloid. Alzheimer's Dement. 2008, 3:S196.
26. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
27. Sohn J.-H., So J.O., Hong H.J., Kim J.W., Na D.R., Kim M., Kim H., Nam E., Ha H.J., Kim Y.H., Mook-Jung I. Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front. Biosci. 2009, 14:3879-3883.
28. Taguchi H., Planque S., Nishiyama Y., Symersky J., Boivin S., Szabo P., Friedland R.P., Ramsland P.A., Edmundson A.B., Weksler M.E., Paul S. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem. 2008, 284:4714-4722.
29. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
30. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37:943-948.